🎉 M&A multiples are live!
Check it out!

Impedimed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Impedimed and similar public comparables like Philips, InfuSystem, and Myomo.

Impedimed Overview

About Impedimed

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of  SOZO Devices, and Software Subscription Services.


Founded

1999

HQ

Australia
Employees

83

Website

impedimed.com

Financials

LTM Revenue $9.0M

LTM EBITDA -$9.0M

EV

$43.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Impedimed Financials

Impedimed has a last 12-month revenue of $9.0M and a last 12-month EBITDA of -$9.0M.

In the most recent fiscal year, Impedimed achieved revenue of $6.4M and an EBITDA of -$13.9M.

Impedimed expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Impedimed valuation multiples based on analyst estimates

Impedimed P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $7.1M $6.4M XXX XXX XXX
Gross Profit $5.6M $6.1M XXX XXX XXX
Gross Margin 78% 97% XXX XXX XXX
EBITDA -$13.0M -$13.9M XXX XXX XXX
EBITDA Margin -182% -219% XXX XXX XXX
Net Profit -$12.6M -$13.0M XXX XXX XXX
Net Margin -177% -204% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Impedimed Stock Performance

As of March 14, 2025, Impedimed's stock price is AUD 0 (or $0).

Impedimed has current market cap of AUD 85.1M (or $53.8M), and EV of AUD 68.4M (or $43.3M).

See Impedimed trading valuation data

Impedimed Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$43.3M $53.8M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Impedimed Valuation Multiples

As of March 14, 2025, Impedimed has market cap of $53.8M and EV of $43.3M.

Impedimed's trades at 4.8x LTM EV/Revenue multiple, and -4.8x LTM EBITDA.

Analysts estimate Impedimed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Impedimed and 10K+ public comps

Impedimed Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $43.3M XXX XXX XXX
EV/Revenue 5.3x XXX XXX XXX
EV/EBITDA -4.0x XXX XXX XXX
P/E -4.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Impedimed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Impedimed Valuation Multiples

Impedimed's NTM/LTM revenue growth is 27%

Impedimed's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Impedimed's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Impedimed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Impedimed and other 10K+ public comps

Impedimed Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -11% XXX XXX XXX XXX
EBITDA Margin -133% XXX XXX XXX XXX
EBITDA Growth 8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -106% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue 5% XXX XXX XXX XXX
G&A Expenses to Revenue 220% XXX XXX XXX XXX
R&D Expenses to Revenue 2% XXX XXX XXX XXX
Opex to Revenue 329% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Impedimed Public Comps

See public comps and valuation multiples for Medical Devices and Health Data & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Myomo XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Impedimed M&A and Investment Activity

Impedimed acquired  XXX companies to date.

Last acquisition by Impedimed was  XXXXXXXX, XXXXX XXXXX XXXXXX . Impedimed acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Impedimed

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Impedimed

When was Impedimed founded? Impedimed was founded in 1999.
Where is Impedimed headquartered? Impedimed is headquartered in Australia.
How many employees does Impedimed have? As of today, Impedimed has 83 employees.
Is Impedimed publicy listed? Yes, Impedimed is a public company listed on ASX.
What is the stock symbol of Impedimed? Impedimed trades under IPD ticker.
When did Impedimed go public? Impedimed went public in 2007.
Who are competitors of Impedimed? Similar companies to Impedimed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem.
What is the current market cap of Impedimed? Impedimed's current market cap is $53.8M
What is the current revenue of Impedimed? Impedimed's last 12-month revenue is $9.0M.
What is the current EBITDA of Impedimed? Impedimed's last 12-month EBITDA is -$9.0M.
What is the current EV/Revenue multiple of Impedimed? Current revenue multiple of Impedimed is 4.8x.
What is the current EV/EBITDA multiple of Impedimed? Current EBITDA multiple of Impedimed is -4.8x.
What is the current revenue growth of Impedimed? Impedimed revenue growth between 2023 and 2024 was -11%.
Is Impedimed profitable? Yes, Impedimed is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.